Schemes for Drug-Induced Treatment of Osteonecrosis of Jaws with Particular Emphasis on the Influence of Vitamin D on Therapeutic Effects by Filip Michalak, Sylwia Hnitecka, Marzena Dominiak, Kinga Grzech-Leśniak

“…In this article, the most important issues related to the treatment of drug-induced osteonecrosis of the jaws (ONJ) are raised, including medication-related osteonecrosis of the jaw (MRONJ); conservative treatment, including the use of laser; and the impact of vitamin D supplementation on the overall treatment, prognosis, and prevention before complication, which is osteonecrosis of the jaw in the course of treatment with bisphosphonates and other drugs predisposing to MRONJ, such as denosumab and angiogenesis inhibitors. The degree of osteonecrosis is also critical, as it is possible to avoid surgical procedures for only conservative methods that sometimes bring good results. …”
Get full text

The Role of the PTEN Tumor Suppressor Gene and Its Anti-Angiogenic Activity in Melanoma and Other Cancers by Jacqueline Maphutha, Danielle Twilley, Namrita Lall

“…Thus, targeted therapies, such as bevacizumab, which targets vascular endothelial growth factor, have been approved by the US Food and Drug Administration (FDA) as angiogenesis inhibitors. The downregulation of the tumor suppressor, phosphatase tensin homolog (PTEN), occurs in 30–40% of human malignant melanomas, thereby elucidating the importance of the upregulation of PTEN activity. …”
Get full text

Intravitreal Dexamethasone Implant for the Treatment of Patient with Resistant to Anti-VEGF Diabetic Macular Edema by M. M. Bikbov, R. M. Zainullin, T. R. Gilmansin, K. I. Kudoyarova, M. R. Kalanov

“…The study was conducted of 24 patients with diabetic macular edema resistant to therapy with angiogenesis inhibitors (3-5 intravitreal injections without a positive structural and functional result) on the background of compensated type 2 diabetes mellitus. …”
Get full text

Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition. by Bainbridge, J, Madden, L, Essex, D, Binks, M, Malhotra, R, Paleolog, E

“…Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased synovial vascularity, and hence is a potential therapeutic target for angiogenesis inhibitors. We examined the use of PPI-2458, a selective non-reversible inhibitor of MetAP-2, in disease models of RA, namely acute and chronic collagen-induced arthritis (CIA) in mice. …”

Nephrotoxicity induced by vascular endothelial growth factor inhibitors by Shirinsadat Badri, Lillian Siberian, Rasool Soltani, Azadeh Moghaddas, Sara Ataei, Mahnaz Momenzadeh

“…VEGF-targeted therapy is categorized into the group of angiogenesis inhibitors that inhibit the expression or the activity of VEGF. …”
Get full text

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese an... by Kazuho Nakanishi, Masafumi Toyoshima, Yuta Ueno, Shunji Suzuki

“…The use of angiogenesis inhibitors and poly ADP-ribose polymerase inhibitors following multi-agent chemotherapy, including platinum-based agents, has become the standard treatment for platinum-sensitive recurrent ovarian cancer (PSROC). …”
Get full text

An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors by Apostolos C. Agrafiotis, Lawek Berzenji, Stien Koyen, Dries Vermeulen, Rachel Winthagen, Jeroen M. H. Hendriks, Paul E. Van Schil

“…Their toxicity profile seems to be acceptable. However, angiogenesis inhibitors do not appear to have a major influence on either thymomas or TC, although multikinase inhibitors may have some effect on TC. …”
Get full text

The Methylation Status of the Epigenome: Its Emerging Role in the Regulation of Tumor Angiogenesis and Tumor Growth, and Potential for Drug Targeting by Luciano Pirola, Oskar Ciesielski, Aneta Balcerczyk

“…Many inhibitors of DNA methylation as well as of histone methylation, have been successfully tested in preclinical studies and some are currently undergoing evaluation in phase I, II or III clinical trials, either as cytostatic molecules—reducing the proliferation of cancerous cells—or as tumor angiogenesis inhibitors. In this review, we will focus on the methylation status of the vascular epigenome, based on the genomic DNA methylation patterns with DNA methylation being mainly transcriptionally repressive, and lysine/arginine histone post-translational modifications which either promote or repress the chromatin transcriptional state. …”
Get full text

In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology by Arlinda Ljoki, Tanzila Aslam, Tina Friis, Ragnhild G. Ohm, Gunnar Houen

“…A co-culture assay with human umbilical vein endothelial cells (HUVECs) and normal human dermal fibroblasts (NHDFs) was used to study whether selected angiogenesis inhibitors were able to inhibit differentiation and network formation of HUVECs in vitro. …”
Get full text

PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. by Edward Hammond, Ralf Brandt, Keith Dredge

“…PG545 is a clinically relevant heparan sulfate (HS) mimetic which, in addition to possessing anti-angiogenic properties, also acts as a heparanase inhibitor which may differentiate its mechanism(s) of action from approved angiogenesis inhibitors. The degradation of HS by heparanase has been strongly implicated in cell dissemination and the metastatic process. …”
Get full text

Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds by Hassan Y. Ebrahim, Khalid A. El Sayed

“…Accepted structures were subjected to in vitro screening to discover mechanistically novel angiogenesis inhibitors. Active hits were subjected to additional angiogenesis-targeted kinase profiling. …”
Get full text

Pan-cancer analysis of chromothripsis-related gene expression patterns indicates an association with tumor immune and therapeutic agent responses by Qin Zhang, Lujie Yang, He Xiao, Zhaoqian Dang, Xunjie Kuang, Yanli Xiong, Jianwu Zhu, Zhou Huang, Mengxia Li

“…In addition, the CHP score was found to be related to resistance against a variety of anti-tumor drugs, including anti-angiogenesis inhibitors and platinum genotoxins, while EGFR pathway inhibitors were found to possibly be sensitizers for high CHP score tumors. …”
Get full text

Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme by Shuhua Zheng, Wensi Tao

“…We identified <i>SOCS3</i> expression levels as a potential selection marker for patients who may benefit from early initiation of angiogenesis inhibitors.…”
Get full text

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma by Massimiliano Salati, Massimiliano Salati, Francesco Caputo, Alessandro Bocconi, Sara Cerri, Cinzia Baldessari, Federico Piacentini, Massimo Dominici, Fabio Gelsomino

“…While phase III randomized trials testing the anti-VEGFR-2 antibody Ramucirumab and the selective VEGFR-2 tyrosine kinase inhibitor Apatinib demonstrated a significant survival benefit in later lines, the shift of angiogenesis inhibitors in the perioperative and first-line setting failed to improve patients’ outcome in GEAs. …”
Get full text

Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises by Aikaterini Skorda, Marie Lund Bay, Sampsa Hautaniemi, Alexandra Lahtinen, Tuula Kallunki

“…Despite the latest therapeutical advancements following the introduction of vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors and poly-ADP-ribose-polymerase (PARP) inhibitors to supplement the standard platinum- and taxane-based chemotherapy, the expected overall survival of HGSC patients has not improved significantly from the five-year rate of 42%. …”
Get full text

Recombinant Human Arresten and Canstatin Inhibit Angiogenic Behaviors of HUVECs via Inhibiting the PI3K/Akt Signaling Pathway by Lingyu Zhu, Zitao Guo, Ji Zhang, Yuliang Yang, Chunyu Liu, Liang Zhang, Zhenghua Gu, Youran Li, Zhongyang Ding, Guiyang Shi

“…Angiogenetic inhibitors are crucial in tumor therapy, and endogenous angiogenesis inhibitors have attracted considerable attention due to their effectiveness, safety, and multi-targeting ability. …”
Get full text

Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma by Hoi-Hin Kwok, Jiashuang Yang, David Chi-Leung Lam

“…Lung adenocarcinoma (ADC) harboring actionable genetic alternations including epidermal growth factor receptor (<i>EGFR</i>), anaplastic lymphoma kinase (<i>ALK</i>), Kirsten rat sarcoma virus (<i>ALK</i>) and c-ros oncogene 1 (<i>ROS1</i>) treated with tyrosine kinase inhibitors (TKIs) incurred lesser treatment toxicity but better therapeutic responses compared with systemic chemotherapy. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) have also shown an increase in overall survival (OS) for NSCLC patients. …”
Get full text

Identification of Aging and Young Subtypes for Predicting Colorectal Cancer Prognosis and Immunotherapy Responses by Lulu Tan, Xiakeerzhati Xiaohalati, Feng Liu, Jia Liu, Haoyu Fu, Yang Zhang, Jinbo Gao, Kaixiong Tao, Guobin Wang, Lin Wang, Zheng Wang

“…The aging subtype was characterized by upregulation of senescence-associated secretory phenotype, higher frequencies of TP53 and immune checkpoint molecules, and high sensitivity to protein kinase and angiogenesis inhibitors. Furthermore, 14 genes were selected by LASSO penalized Cox regression analyses for aging-related risk signature construction. …”
Get full text

Matrilin-1 Is an Inhibitor of Neovascularization by Foradori, Matthew J., Harper, Jay, Li, Xin, Tsang, Paul C. W., Moses, Marsha A., Chen, Qian, Fernandez, Cecilia A, Langer, Robert S

“…In the course of conducting a series of studies whose goal was to discover novel endogenous angiogenesis inhibitors, we have purified Matrilin-1 (MATN-1) and have demonstrated, for the first time, that it inhibits neovascularization both in vitro and in vivo. …”
Get full text
Get full text
Get full text

Targeting Angiogenesis in Cancer Treatments: Where do we Stand? by Nenad Petrovic

“…Intensive research in the last twenty years resulted in identification of more than 300 angiogenesis inhibitors, a trend that is expected to continue. …”
Get full text